Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
about
Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumabIndirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.Emerging antiangiogenics for renal cancer.A review of economic impact of targeted oral anticancer medications.A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
P2860
Q34193184-ED8A2771-4ACB-4D73-B8A1-54A52B1A16A1Q34417804-1060ACC7-9938-4AE0-8555-BD4F33177FAAQ35205445-806AA1A4-C28F-4108-B2F4-1019AC607B2CQ36001592-D387C680-4AF1-4307-A985-05A857B75874Q36212489-EFC15BC3-A3C7-4A2E-8832-ADD1199A7E53Q37330372-1AB16073-6D2C-46BE-97BC-A5C95C8BC93AQ37587205-7DEF2D82-782B-499A-B993-5A3425A4798CQ37838448-12A5EA70-8023-4010-8B11-7990B896B5FEQ37914888-DB80D45A-570C-447E-A9EC-3324A023FC1AQ38166015-83ADE525-A696-43B6-AB28-A0C3361925B6Q38174702-63EAE434-4BAA-47D5-8B18-7FE0C5FDC17BQ38598931-E50F2F10-5EA7-403D-87E7-A9EAE7BF88B4Q39582489-EFC4FEF0-4A38-44F5-A5F5-399003B4652BQ42392542-CA217EAA-898C-46E2-AC51-44975B0B7CDDQ42843110-CC1C0911-8EE6-447B-B6BF-78C30908B6DCQ46481747-0E3FE667-00B3-4C0A-8BED-DD5EBCC64292Q47574970-39FEEE79-69F9-45EE-BF15-B863D0FD6571
P2860
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Costs of managing adverse even ...... pha2a compared with sunitinib.
@ast
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
type
label
Costs of managing adverse even ...... pha2a compared with sunitinib.
@ast
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
prefLabel
Costs of managing adverse even ...... pha2a compared with sunitinib.
@ast
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
P2093
P2860
P356
P1476
Costs of managing adverse even ...... pha2a compared with sunitinib.
@en
P2093
P2860
P2888
P356
10.1038/SJ.BJC.6605417
P407
P577
2009-11-17T00:00:00Z
P5875
P6179
1015902157